Alaunos Therapeutics Prices $1.12M Direct Offering; Shares Drop 17%

Alaunos Prices $1.12 Million Registered Direct Offering

Alaunos Therapeutics, Inc. (Nasdaq: TCRT) said on Sept. 18, 2026, that it had entered into definitive agreements with institutional investors for a registered direct offering of 380,469 shares of common stock and pre-funded warrants to purchase up to 386,654 shares at $1.46 per share, yielding aggregate gross proceeds of approximately $1,120,000 before placement-agent fees and expenses. The transaction was priced at-the-market under Nasdaq rules, with Dawson James Securities, Inc. acting as sole placement agent. Securities are being offered under the company's effective shelf registration statement on Form S-3 (File No. 333-289748), initially filed with the U.S. Securities and Exchange Commission on Nov. 11, 2025 and effective Dec. 1, 2025.

Shares Slide as Market Reacts to Capital Raise

Following the announcement, Alaunos shares fell roughly 16.81%, shedding about $0.27 to trade around $1.3303 in U.S. trading on Sept. 18, 2026, reflecting investor concern over dilution from the issuance of new common stock and pre-funded warrants at a depressed price.

Use of Proceeds and Pipeline Context

Alaunos said net proceeds will be used primarily for general working capital and corporate purposes. The Fort Lauderdale, Florida-based biotechnology company is developing novel therapeutics, with its obesity and metabolic disorders program advancing ALN1003, an oral small-molecule candidate being evaluated as a potential non-hormonal, non-incretin approach for obesity- and metabolic-disease-relevant biology.

Expected Closing and Closing-Condition Risk

The offering is expected to close on or about Sept. 21, 2026, subject to customary closing conditions, a timeline that leaves a brief window in which financing could be delayed or prevented if those conditions are not satisfied.